Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Sorafenib plus GCLAM yielded 83% complete response rate in AML, MDS

Key clinical point: Sorafenib plus granulocyte colony–stimulating factor, cladribine, high-dose cytarabine, and mitoxantrone appears safe and effective for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndromes.

Major finding: The complete response rate was 83%; the most common treatment-related adverse event was grade 3 febrile neutropenia, seen in 90% of patients.

Study details: A phase 1 trial of 47 patients with acute myeloid leukemia or myelodysplastic syndromes age 60 years and younger.

Disclosures: The trial was sponsored by the University of Washington, Seattle, in collaboration with the National Cancer Institute, and funding was provided by Bayer. The researchers reported no conflicts of interest.

Citation:

REPORTING FROM ALF 2019